Medexus Pharmaceuticals Inc.
MDP.TO
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 99.33M | 99.43M | 104.10M | 105.66M | 108.33M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 99.33M | 99.43M | 104.10M | 105.66M | 108.33M |
| Cost of Revenue | 35.48M | 36.44M | 40.15M | 42.21M | 44.82M |
| Gross Profit | 63.86M | 63.00M | 63.95M | 63.45M | 63.51M |
| SG&A Expenses | 45.89M | 47.47M | 47.23M | 45.00M | 43.18M |
| Depreciation & Amortization | 9.73M | 9.71M | 9.05M | 8.19M | 7.18M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 93.50M | 95.55M | 98.11M | 97.22M | 96.41M |
| Operating Income | 5.84M | 3.89M | 5.99M | 8.44M | 11.92M |
| Income Before Tax | -2.27M | -25.00K | 409.00K | 155.00K | 1.44M |
| Income Tax Expenses | 120.00K | 247.00K | 28.00K | -651.00K | -807.00K |
| Earnings from Continuing Operations | -2.39 | -0.27 | 0.38 | 0.81 | 2.25 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.39M | -272.00K | 381.00K | 806.00K | 2.25M |
| EBIT | 5.84M | 3.89M | 5.99M | 8.44M | 11.92M |
| EBITDA | 15.39M | 13.44M | 14.88M | 16.48M | 18.94M |
| EPS Basic | -0.07 | -0.01 | 0.02 | 0.03 | 0.10 |
| Normalized Basic EPS | 0.01 | -0.04 | -0.03 | 0.02 | 0.08 |
| EPS Diluted | -0.07 | -0.01 | 0.02 | 0.03 | 0.10 |
| Normalized Diluted EPS | 0.01 | -0.04 | -0.03 | 0.02 | 0.08 |
| Average Basic Shares Outstanding | 129.27M | 126.58M | 118.83M | 111.09M | 103.29M |
| Average Diluted Shares Outstanding | 129.27M | 126.58M | 118.83M | 111.94M | 104.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |